vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and PETMED EXPRESS INC (PETS). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $40.7M, roughly 1.5× PETMED EXPRESS INC). PETMED EXPRESS INC runs the higher net margin — -26.0% vs -70.9%, a 45.0% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -23.3%). Cytek Biosciences, Inc. produced more free cash flow last quarter ($-1.8M vs $-9.2M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -20.9%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication.
CTKB vs PETS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $40.7M |
| Net Profit | $-44.1M | $-10.6M |
| Gross Margin | 52.9% | 23.3% |
| Operating Margin | -9.0% | -25.7% |
| Net Margin | -70.9% | -26.0% |
| Revenue YoY | 8.1% | -23.3% |
| Net Profit YoY | -557.1% | -1392.6% |
| EPS (diluted) | — | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $40.7M | ||
| Q3 25 | $52.3M | $44.4M | ||
| Q2 25 | $45.6M | $51.2M | ||
| Q1 25 | $41.5M | $50.8M | ||
| Q4 24 | $57.5M | $52.0M | ||
| Q3 24 | $51.5M | $58.0M | ||
| Q2 24 | $46.6M | $66.2M | ||
| Q1 24 | $44.9M | $65.1M |
| Q4 25 | $-44.1M | $-10.6M | ||
| Q3 25 | $-5.5M | $-8.5M | ||
| Q2 25 | $-5.6M | $-34.2M | ||
| Q1 25 | $-11.4M | $-11.6M | ||
| Q4 24 | $9.6M | $-707.0K | ||
| Q3 24 | $941.0K | $2.3M | ||
| Q2 24 | $-10.4M | $3.8M | ||
| Q1 24 | $-6.2M | $-5.0M |
| Q4 25 | 52.9% | 23.3% | ||
| Q3 25 | 52.7% | 28.0% | ||
| Q2 25 | 52.3% | 28.1% | ||
| Q1 25 | 48.6% | 29.9% | ||
| Q4 24 | 58.5% | 31.0% | ||
| Q3 24 | 56.3% | 32.3% | ||
| Q2 24 | 54.6% | 28.8% | ||
| Q1 24 | 51.3% | 29.3% |
| Q4 25 | -9.0% | -25.7% | ||
| Q3 25 | -17.6% | -18.9% | ||
| Q2 25 | -23.3% | -66.7% | ||
| Q1 25 | -36.1% | -11.9% | ||
| Q4 24 | 5.2% | -0.9% | ||
| Q3 24 | -8.2% | 1.0% | ||
| Q2 24 | -18.3% | 6.6% | ||
| Q1 24 | -23.9% | -5.9% |
| Q4 25 | -70.9% | -26.0% | ||
| Q3 25 | -10.5% | -19.2% | ||
| Q2 25 | -12.2% | -66.7% | ||
| Q1 25 | -27.5% | -22.9% | ||
| Q4 24 | 16.8% | -1.4% | ||
| Q3 24 | 1.8% | 4.0% | ||
| Q2 24 | -22.4% | 5.7% | ||
| Q1 24 | -13.8% | -7.7% |
| Q4 25 | — | $-0.50 | ||
| Q3 25 | — | $-0.41 | ||
| Q2 25 | — | $-1.65 | ||
| Q1 25 | — | $-0.56 | ||
| Q4 24 | — | $-0.03 | ||
| Q3 24 | — | $0.11 | ||
| Q2 24 | — | $0.18 | ||
| Q1 24 | — | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $26.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $32.8M |
| Total Assets | $461.5M | $88.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $26.9M | ||
| Q3 25 | $93.3M | $36.1M | ||
| Q2 25 | $75.5M | $41.1M | ||
| Q1 25 | $95.3M | $54.7M | ||
| Q4 24 | $98.7M | $50.1M | ||
| Q3 24 | $162.3M | $52.0M | ||
| Q2 24 | $177.9M | $46.0M | ||
| Q1 24 | $168.8M | $55.3M |
| Q4 25 | $341.7M | $32.8M | ||
| Q3 25 | $378.6M | $43.1M | ||
| Q2 25 | $377.6M | $51.5M | ||
| Q1 25 | $379.6M | $85.1M | ||
| Q4 24 | $395.7M | $96.2M | ||
| Q3 24 | $385.5M | $96.4M | ||
| Q2 24 | $389.1M | $93.5M | ||
| Q1 24 | $392.6M | $96.7M |
| Q4 25 | $461.5M | $88.0M | ||
| Q3 25 | $494.9M | $100.3M | ||
| Q2 25 | $493.3M | $109.8M | ||
| Q1 25 | $482.6M | $148.7M | ||
| Q4 24 | $499.5M | $144.8M | ||
| Q3 24 | $491.2M | $146.0M | ||
| Q2 24 | $483.7M | $152.7M | ||
| Q1 24 | $492.1M | $169.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $-9.2M |
| Free Cash FlowOCF − Capex | $-1.8M | $-9.2M |
| FCF MarginFCF / Revenue | -2.9% | -22.7% |
| Capex IntensityCapex / Revenue | 1.6% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $-23.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $-9.2M | ||
| Q3 25 | $-3.9M | $-2.2M | ||
| Q2 25 | $108.0K | $-12.3M | ||
| Q1 25 | $-125.0K | $7.0M | ||
| Q4 24 | $2.0M | $-1.2M | ||
| Q3 24 | $13.2M | $7.4M | ||
| Q2 24 | $6.2M | $-8.5M | ||
| Q1 24 | $4.0M | $7.1M |
| Q4 25 | $-1.8M | $-9.2M | ||
| Q3 25 | $-4.6M | $-4.8M | ||
| Q2 25 | $-1.5M | $-13.6M | ||
| Q1 25 | $-974.0K | $4.6M | ||
| Q4 24 | $1.1M | $-1.9M | ||
| Q3 24 | $12.2M | $6.1M | ||
| Q2 24 | $5.2M | $-9.2M | ||
| Q1 24 | $3.4M | $5.9M |
| Q4 25 | -2.9% | -22.7% | ||
| Q3 25 | -8.7% | -10.8% | ||
| Q2 25 | -3.2% | -26.5% | ||
| Q1 25 | -2.3% | 9.1% | ||
| Q4 24 | 1.9% | -3.7% | ||
| Q3 24 | 23.7% | 10.6% | ||
| Q2 24 | 11.0% | -13.9% | ||
| Q1 24 | 7.6% | 9.0% |
| Q4 25 | 1.6% | 0.1% | ||
| Q3 25 | 1.3% | 5.9% | ||
| Q2 25 | 3.5% | 2.5% | ||
| Q1 25 | 2.0% | 4.7% | ||
| Q4 24 | 1.6% | 1.5% | ||
| Q3 24 | 2.0% | 2.2% | ||
| Q2 24 | 2.3% | 1.0% | ||
| Q1 24 | 1.3% | 1.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | 3.18× | ||
| Q2 24 | — | -2.27× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
PETS
| Reorder | $34.0M | 84% |
| New Order | $5.0M | 12% |
| Membership Fees | $1.6M | 4% |
